Editorial: Curcuminoids: their pleiotropism against hallmarks of cancers

Daniel L Pouliquen; Koraljka Gall Trošelj; Ruby John Anto; Rakesh Naidu

doi:10.3389/fphar.2023.1266793

Editorial: Curcuminoids: their pleiotropism against hallmarks of cancers

Front Pharmacol. 2023 Aug 18:14:1266793. doi: 10.3389/fphar.2023.1266793. eCollection 2023.

Authors

Daniel L Pouliquen¹, Koraljka Gall Trošelj², Ruby John Anto³, Rakesh Naidu⁴

Affiliations

¹ Inserm, CNRS, Nantes Université, CRCI2NA, Université d'Angers, Angers, France.
² Laboratory for Epigenomics, Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.
³ Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
⁴ Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Malaysia.

No abstract available

Keywords: clinical trials; combined therapy; curcumin; curcumin analogs; molecular mechanism; molecular targets; nano-formulations; signaling pathways.

Publication types

Editorial